Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JONATHAN W HODGSON

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1851345433
CMS profile
38154
Location
GILBERT, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$69,439.77

417 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $40,232.44 107
Lilly USA, LLC $17,695.42 48
Lundbeck LLC $3,826.48 11
Eli Lilly and Company $1,627.10 2
Genentech, Inc. $1,335.00 1
Biohaven Pharmaceutical Holding Company Ltd. $451.11 35
GENZYME CORPORATION $410.17 11
Amgen Inc. $358.53 15
Teva Pharmaceuticals USA, Inc. $298.98 13
Novartis Pharmaceuticals Corporation $251.76 15
Horizon Therapeutics plc $220.83 5
CSL Behring $200.54 4
Biogen, Inc. $191.18 11
Avion Pharmaceuticals $181.09 10
UCB, Inc. $147.30 6
UPSHER-SMITH LABORATORIES LLC $145.40 13
ACADIA Pharmaceuticals Inc $144.49 10
Allergan, Inc. $140.96 9
Neurocrine Biosciences, Inc. $136.85 10
IMPEL PHARMACEUTICALS INC. $130.49 9
Alexion Pharmaceuticals, Inc. $128.79 7
MDD US Operations, LLC $124.26 7
Amneal Pharmaceuticals LLC $95.59 5
ARGENX US, INC. $79.14 4
SK Life Science, Inc. $76.32 3
Banner Life Sciences, LLC $62.09 4
Medtronic, Inc. $55.40 3
Corium, LLC $54.97 3
EISAI INC. $52.94 3
Genentech USA, Inc. $50.17 2
CATALYST PHARMACEUTICALS, INC. $49.97 3
Janssen Pharmaceuticals, Inc $49.71 3
Collegium Pharmaceutical, Inc. $47.01 3
Celgene Corporation $45.89 3
Merz Pharmaceuticals, LLC $44.99 1
Supernus Pharmaceuticals, Inc. $38.38 2
Abbott Laboratories $37.32 2
Avanir Pharmaceuticals, Inc. $29.44 2
Cala Health, Inc. $26.19 1
Aprecia Pharmaceuticals, LLC $24.37 1
Kyowa Kirin, Inc. $24.03 1
EMD Serono, Inc. $23.31 1
Alnylam Pharmaceuticals Inc. $20.71 1
Neurelis, Inc. $17.03 1
MITSUBISHI TANABE PHARMA AMERICA, INC. $16.47 1
Grifols USA, LLC $14.65 1
Acorda Therapeutics, Inc $12.30 1
Metacel Pharmaceuticals LLC $10.55 1
Travere Therapeutics, Inc. $1.66 2

Page 3 of 9; records 101–150 of 417 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JONATHAN W HODGSON

NPI 1851345433 · CMS profile ID 38154

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

GILBERT, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 9; records 101–150 of 417 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1851345433?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JONATHAN W HODGSON, NPI 1851345433, CMS profile ID 38154. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 9; records 101–150 of 417 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851345433?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JONATHAN W HODGSON, NPI 1851345433, CMS profile ID 38154. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 9; records 101–150 of 417 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851345433?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JONATHAN W HODGSON, NPI 1851345433, CMS profile ID 38154, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 9; records 101–150 of 417 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1851345433?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

417 matching records · $69,439.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 417 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 417.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $34.0209/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954631095 CMS
ABBVIE INC. $9.4309/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892830963 CMS
Biohaven Pharmaceutical Holding Company Ltd. $5.1209/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923617437 CMS
Lilly USA, LLC $14.9309/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918167227 CMS
Neurocrine Biosciences, Inc. $14.7309/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963296215 CMS
ABBVIE INC. $4.9009/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892830959 CMS
ACADIA Pharmaceuticals Inc $17.4609/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952382803 CMS
Biogen, Inc. $6.2909/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923387267 CMS
Amgen Inc. $18.8609/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939238925 CMS
ABBVIE INC. $9.9209/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892830955 CMS
Biohaven Pharmaceutical Holding Company Ltd. $4.7509/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923617433 CMS
Biohaven Pharmaceutical Holding Company Ltd. $17.0709/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923617435 CMS
ABBVIE INC. $11.6509/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892830951 CMS
ABBVIE INC. $5.8109/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892830947 CMS
Amneal Pharmaceuticals LLC $19.1909/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956581661 CMS
Janssen Pharmaceuticals, Inc $18.6409/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885693837 CMS
ABBVIE INC. $8.8109/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892830945 CMS
Biohaven Pharmaceutical Holding Company Ltd. $6.4309/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923617431 CMS
Horizon Therapeutics plc $13.2009/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937633879 CMS
ABBVIE INC. $13.6709/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892830941 CMS
Horizon Therapeutics plc $0.6909/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937633877 CMS
Teva Pharmaceuticals USA, Inc. $13.7109/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954630719 CMS
ABBVIE INC. $4.1209/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892830933 CMS
ABBVIE INC. $27.4009/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892830937 CMS
Teva Pharmaceuticals USA, Inc. $1.7309/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954631123 CMS
UPSHER-SMITH LABORATORIES LLC $3.2909/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 912308903 CMS
UPSHER-SMITH LABORATORIES LLC $20.7608/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 912308971 CMS
ARGENX US, INC. $27.6108/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951634767 CMS
ABBVIE INC. $2.0708/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892830927 CMS
ABBVIE INC. $3.1608/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892830931 CMS
Amgen Inc. $9.0408/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939238923 CMS
GENZYME CORPORATION $28.7108/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938946009 CMS
ABBVIE INC. $24.6908/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892830919 CMS
ABBVIE INC. $2,400.0008/26/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892830923 CMS
ABBVIE INC. $18.1408/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892830917 CMS
Alexion Pharmaceuticals, Inc. $22.6308/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915806893 CMS
Novartis Pharmaceuticals Corporation $23.1008/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893751233 CMS
Eli Lilly and Company $27.1008/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918167231 CMS
Amgen Inc. $21.9408/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939238921 CMS
Banner Life Sciences, LLC $15.3708/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957721641 CMS
CATALYST PHARMACEUTICALS, INC. $17.2908/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950297091 CMS
Supernus Pharmaceuticals, Inc. $17.3008/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952972817 CMS
ABBVIE INC. $14.5708/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892830913 CMS
Biohaven Pharmaceutical Holding Company Ltd. $5.7708/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923617429 CMS
GENZYME CORPORATION $111.1908/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938946007 CMS
EMD Serono, Inc. $23.3108/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941551735 CMS
ABBVIE INC. $25.2008/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892830909 CMS
Avion Pharmaceuticals $17.3108/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926519963 CMS
Collegium Pharmaceutical, Inc. $19.8408/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914531021 CMS
Teva Pharmaceuticals USA, Inc. $34.9208/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954630923 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $23,800.31 335
PY2020 $53,074.73 253
PY2021 $89,831.28 362
PY2022 $69,439.77 417
PY2023 $32,004.97 393
PY2024 $71,362.13 316
PY2025 $68,604.78 185

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $275,701.83 25
PY2024 Principal investigator $214,356.31 16
PY2023 Recipient $372.40 1
PY2023 Principal investigator $264,058.35 10
PY2022 Recipient $1,630.00 2
PY2022 Principal investigator $343,018.65 15
PY2021 Recipient $2,855.10 1
PY2021 Principal investigator $243,879.56 6
PY2020 Recipient $14,577.94 3
PY2020 Principal investigator $22,051.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202532685
Principal investigator 1 ABBVIE INC. $1,497.30 12/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202526602
Principal investigator 1 ABBVIE INC. $3,381.00 12/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202526604
Principal investigator 1 ABBVIE INC. $20,734.50 11/05/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202521375
Principal investigator 1 ABBVIE INC. $510.60 11/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202521219
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $200.50 10/27/2025 Non-covered Recipient Entity
Gilbert Neurology Partners Pllc
Phase III Safety and Efficacy of KarXT in Psychosis Associated with AD (ADEPT 4): 2 of 2 Acute Studies No dispute reported 06/30/2026 1235997089
Principal investigator 1 ABBVIE INC. $765.90 10/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202514219
Principal investigator 1 ABBVIE INC. $21,583.20 10/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202514225
Principal investigator 1 ABBVIE INC. $483.00 09/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202509602
Principal investigator 1 ABBVIE INC. $7,555.50 08/06/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202503565
Principal investigator 1 ABBVIE INC. $675.60 08/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202501028
Principal investigator 1 ABBVIE INC. $1,792.80 07/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202497678
Principal investigator 1 ABBVIE INC. $1,021.20 07/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202497680
Principal investigator 1 ABBVIE INC. $1,005.60 07/08/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202497478
Principal investigator 1 ABBVIE INC. $5,037.00 07/02/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202496617
Principal investigator 1 ABBVIE INC. $11,888.70 06/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202491141
Principal investigator 1 ABBVIE INC. $22,735.50 05/07/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202482999
Principal investigator 1 ABBVIE INC. $330.00 05/06/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202481599
Principal investigator 1 ABBVIE INC. $15,476.70 04/03/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202472885
Principal investigator 1 ABBVIE INC. $14,441.70 03/07/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202460359
Principal investigator 1 ABBVIE INC. $6,969.00 02/06/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202447264
Principal investigator 1 Sage Therapeutics, LLC $18,550.60 01/31/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS, LLC
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 1206580750
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,269.83 01/27/2025 Non-covered Recipient Entity
Gilbert Neurology
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235997091
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $111,540.10 01/13/2025 Non-covered Recipient Entity
Gilbert Neurology
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235997093
Principal investigator 1 ABBVIE INC. $1,656.00 01/02/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202433855